Exco InTouch Launches New Mobile Tech
Gather™ is an integrated technology system that can be accessed through any internet-connected device and uses a module-based product suite.
Exco InTouch, a provider of patient engagement and data capture solutions for clinical research and healthcare providers, announces Gather™, its integrated technology system that can be accessed through any internet-connected device and replaces independent technology systems used in clinical trials with a module-based product suite.
Primary modules--or products within the suite--include Study Design, Workflow Integration and Study Management for sites and sponsors. For patients, modules are Enrollment, Patient Engagement and eCOA.
Gather™ provides two-way transfer of information between stakeholders and provides a role-based permissions user interface, providing appropriate levels of access, reporting and analytics according to the registered user. For example, Gather™ provides site investigators, healthcare professionals and study managers access to a tailored view of relevant data and results. The interface also ensures identifiable information (PII) is protected.
Read the full release.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
